Date: 2015-01-08
Type of information: Nomination
Compound:
Company: Cardio3 BioSciences (Belgium)
Therapeutic area: Cardiovascular diseases - Regenerative Medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 8, 2015, Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announced the appointment of Dr. Vincent Brichard as Vice President immuno-oncology. In this role, Dr. Brichard will lead the newly acquired immuno-oncology technology platform of Cardio3BioSciences. Vincent Brichard is a physician by training, specialized in oncology, and holds a PhD in tumor immunology. He started his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of
Louvain, Brussels. In 2002, he joined GlaxoSmithKline Biologicals, where he led the Cancer Vaccines Business Unit. Until recently, Vincent was the Senior Vice President of the Immunotherapeutics Business Unit, and member of the Vaccines Executive team at GSK Biologicals. Vincent Brichard will give all support required to build another asset of the Company, by driving, from preclinical towards commercialisation, the development of the products of the immunooncology platform.
Financial terms:
Latest news:
